Gilead Sciences (GILD) EBITDA (2009 - 2026)

Gilead Sciences (GILD) has reported EBITDA for 18 consecutive years, with -$10.4 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA fell 520.13% year-over-year to -$10.4 billion; the trailing twelve-month figure through Jun 2026 stood at -$2.5 billion (down 131.01% YoY), and the FY2025 full-year result was $10.0 billion, up 503.01% from the prior year.
• EBITDA fell to -$10.4 billion in Q2 2026 per GILD's latest filing, from $2.6 billion in the prior quarter.
• Across five years, EBITDA topped out at $3.3 billion in Q3 2025 and bottomed at -$10.4 billion in Q2 2026.
• Historically, EBITDA has averaged $1.0 billion across 5 years, with a median of $2.1 billion in 2022.
• The sharpest annual moves came in 2023 and 2026: EBITDA jumped 765.48% in 2023, then sank 520.13% in 2026.
• Over 5 years, EBITDA stood at $2.3 billion in 2022, then declined by 28.89% to $1.6 billion in 2023, then surged by 52.11% to $2.5 billion in 2024, then decreased by 19.09% to $2.0 billion in 2025, then slumped by 623.89% to -$10.4 billion in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$10.4 billion, $2.6 billion, and $2.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.